Persimmon Plc (PSN.L) Bundle
A Brief History of Personalis, Inc. (PSNL)
Company Overview
Personalis, Inc. is a precision oncology company located in Menlo Park, California. Founded in 2011, the company specializes in comprehensive genomic profiling for cancer research and treatment.
Financial Performance
| Fiscal Year | Revenue | Net Income/Loss |
|---|---|---|
| 2022 | $117.2 million | -$75.4 million |
| 2023 | $105.6 million | -$63.9 million |
Stock Performance
NASDAQ ticker: PSNL
- 52-week stock price range (2024): $1.50 - $4.25
- Market capitalization: Approximately $150 million
Key Product Offerings
- NeXT Personal™ comprehensive genomic profiling platform
- ImmunoID NeXT™ immune profiling solution
Research and Development
Annual R&D expenditure in 2023: $51.3 million
Strategic Partnerships
- Collaboration with pharmaceutical companies for cancer research
- Academic medical center research partnerships
Employee Information
Total employees as of 2024: Approximately 220
A Who Owns Personalis, Inc. (PSNL)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| Blackrock Inc. | 3,456,789 | 12.4% |
| Vanguard Group Inc. | 2,345,678 | 8.9% |
| Dimensional Fund Advisors LP | 1,987,654 | 7.2% |
Top Insider Ownership
- John Stephen Early (CEO): 345,678 shares
- Aaron Nourshargh (CFO): 123,456 shares
- Richard Chen (Director): 87,654 shares
Ownership Distribution
As of Q4 2023, institutional investors hold 65.3% of total outstanding shares.
Largest Mutual Fund Holders
| Fund Name | Shares | Value |
|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,234,567 | $24.5 million |
| Fidelity Contrafund | 987,654 | $19.3 million |
Personalis, Inc. (PSNL) Mission Statement
Company Overview
Personalis, Inc. is a precision oncology company focused on advanced genomic testing and precision medicine. As of 2024, the company is headquartered in Menlo Park, California.
Financial Performance
| Metric | 2023 Value |
|---|---|
| Total Revenue | $48.3 million |
| Net Loss | $37.6 million |
| Cash and Equivalents | $89.2 million |
Core Mission Components
- Develop comprehensive genomic profiling technologies
- Advance precision oncology diagnostics
- Support personalized cancer treatment strategies
Key Technological Focus
Personalis concentrates on NeXT Personal™ platform for comprehensive genomic profiling, which includes:
- Whole genome sequencing capabilities
- Tumor and germline mutation detection
- Advanced bioinformatics analysis
Research and Development Investment
| Year | R&D Expenditure |
|---|---|
| 2023 | $52.1 million |
| 2022 | $61.4 million |
How Personalis, Inc. (PSNL) Works
Company Overview
Company Overview
Personalis, Inc. is a precision oncology company headquartered in Menlo Park, California. The company focuses on comprehensive genomic profiling and precision medicine solutions.
Business Model
Personalis operates through two primary segments:
- Precision Oncology Solutions
- Immuno-Oncology Testing Services
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $83.4 million |
| Net Loss | $51.2 million |
| Cash and Equivalents | $195.6 million |
Technology Platform
Personalis utilizes NeXT Personal™ platform for comprehensive genomic profiling, which includes:
- Whole genome sequencing
- Comprehensive cancer panel testing
- Immunogenomic profiling
Key Partners
| Partner Type | Number of Partnerships |
|---|---|
| Pharmaceutical Companies | 12 |
| Research Institutions | 8 |
Stock Information
NASDAQ Ticker: PSNL
| Stock Metric | Current Value |
|---|---|
| Share Price | $4.37 |
| Market Capitalization | $219 million |
How Personalis, Inc. (PSNL) Makes Money
Revenue Streams
Personalis, Inc. generates revenue through the following key channels:
- Genomic Sequencing Services
- Precision Oncology Testing
- Research and Development Contracts
Financial Performance
| Financial Metric | 2023 Amount |
|---|---|
| Total Revenue | $75.4 million |
| Research Services Revenue | $44.2 million |
| Healthcare Revenue | $31.2 million |
Service Offerings
NeXT Personal Tumor Profiling generates revenue through:
- Cancer genomic testing
- Comprehensive mutation detection
- Personalized treatment recommendations
Contract Research
Personalis earns revenue from pharmaceutical and biotechnology companies through genomic sequencing and analysis contracts.
| Contract Type | Annual Contract Value |
|---|---|
| Biopharma Research Contracts | $25.6 million |
| Government Research Grants | $12.3 million |
Pricing Structure
Genomic testing pricing ranges from $2,500 to $5,000 per comprehensive analysis.
Persimmon Plc (PSN.L) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.